Key result
Ponatinib is linked to a higher incidence of cardiovascular events versus other TKIs.
Why the study?
Tyrosine kinase inhibitors have advanced treatment for Philadelphia chromosome-positive CML, but the incidence of cardiovascular adverse events needed evaluation.
Does the choice of tyrosine kinase inhibitor affect the incidence of cardiovascular adverse events in patients with chronic myeloid leukaemia?
Observational (n=61)
No
Does the choice of tyrosine kinase inhibitor affect the incidence of cardiovascular adverse events in patients with chronic myeloid leukaemia?
p-value: p=<0.05
In patients with CML, ponatinib is associated with a significantly higher incidence of cardiovascular events compared to other tyrosine kinase inhibitors.
Background The introduction of imatinib and tyrosine kinase inhibitors as therapeutic strategy for Philadelphia chromosome-positive chronic myeloid leukaemia (CML) has represented an important step forward for treatment of this disease. The aim of this study was therefore to evaluate the incidence of cardiovascular adverse events (CVEs) in patients affected by CML treated with TKI in an observational prospective study.Methods All consecutive patients affected by CML and treated with TKI in our Institution were enrolled in the study from February 2005 to September 2018 with a clinical, laboratory and instrumental follow-up.Results Sixty-one consecutive patients were enrolled, 29 with imatinib, 15 with nilotinib, 11 with dasatinib, 3 with bosutinib and 3 with ponatinib. Neither patients in therapy with bosutinib nor with nilotinib had CVE during follow-up. Incidence rates per person/year were 0 for bosutinib and nilotinib, 0.15 for dasatinib, 0.19 for imatinib and 1.69 for ponatinib (Log Rank p < 0.05); differences in terms of incidence of adverse outcomes remained significant also after multivariate correction.Conclusions In patients with CML treated with TKIs, therapy with ponatinib was associated with a higher risk of CVE than other TKIs. The lowest incidence of CVE was associated with bosutinib and nilotinib.
No takes yet. Share an insight, caveat, or question.
Casavecchia et al. (2021) conducted an observational in Chronic myeloid leukaemia (CML) (n=61). Ponatinib vs. Other tyrosine kinase inhibitors (imatinib, nilotinib, dasatinib, bosutinib) was evaluated on Cardiovascular adverse events (CVEs) (p=<0.05). Among patients with chronic myeloid leukaemia, ponatinib exposure was associated with a higher incidence of cardiovascular events (1.69 per person-year) compared to other TKIs (Log Rank P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: